Outcome of patients with brain metastases ( BM ) from non-oncogene addicted non-small cell lung cancer ( NSCLC), treated with systemic anti-cancer therapy alone or in combination with local brain treatment. Experience from Portsmouth Oncology Centre

Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: NSCLC Chemotherapy Source Type: research

Related Links:

Immune checkpoint inhibitors (ICIs) are used as routine initial systemic therapy in patients with metastatic non-small cell lung cancer (mNSCLC). However, the impact of ICIs on the control of brain metastases is unclear. The treatment of brain metastases with systemic therapy has been challenging historically due to poor central nervous system (CNS) penetrance of many agents.1 –3 Small molecule inhibitors, specifically designed to optimize CNS penetrance, have become attractive treatment options for patients with oncogene addicted mNSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: Upfront pembrolizumab showed efficacy in selected patients with PD-L1 ≥ 50% non-oncogene addicted NSCLC and asymptomatic BMs. Prospective studies should address whether pembrolizumab alone, and deferral of radiotherapy, could be pursued in this patient population.PMID:33728869 | DOI:10.1007/s12094-021-02588-8
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsUpfront pembrolizumab showed efficacy in selected patients with PD-L1  ≥ 50% non-oncogene addicted NSCLC and asymptomatic BMs. Prospective studies should address whether pembrolizumab alone, and deferral of radiotherapy, could be pursued in this patient population.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Brain is the most frequent site for distant metastases of non-small cell lung cancer (NSCLC). Brain metastasis (BM) is also the leading cause of disabilities and death in advanced NSCLC. In recent years, the application and effectiveness of small-molecule tyrosine kinase inhibitors has formed the basis for the treatment of NSCLC brain metastases with driver gene mutations. With the development of programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitors and relevant combination therapies, immunotherapy has become an important choice for non-classic oncogene addicted NSCLC BM patients....
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Conclusion The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroinfla...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Liu G Abstract BACKGROUND: In lung cancer, brain metastases (BM) and their treatment are associated with high economic burden and inferior health-related quality of life. In the era of targeted therapy, real world evidence through health utility scores (HUS) is critical for economic analyses. MATERIALS AND METHODS: In a prospective observational cohort study (2014-2016), outpatients with stage IV lung cancer completed demographic and EQ-5D-3L surveys (to derive HUS). Health states and clinicopathologic variables were obtained from chart abstraction. Patients were categorized by the presence or absence of BM; ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
The onset of Brain Metastases (BM) is proportionally greater in lung cancer than in other solid tumors (Barnholtz-Sloan et al., 2004), with significant impact on patients performance status (PS) and prognosis (Ali and Goffin, 2013). Synchronous or metachronous central nervous system (CNS) spread occurs in about 20% and 40% of Non-Small Cell Lung Cancer (NSCLC) cases, respectively (Langer and Mehta, 2005; S ørensen et al., 1988).
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research
J. Remon, Benjamin Besse
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Sgambato A, Casaluce F, Maione P, Gridelli C Abstract INTRODUCTION: Anaplastic lymphoma kinase (ALK) and ROS1 rearrangements define important molecular subgroups of advanced non-small cell lung cancer (NSCLC). The identification of these genetic driver alterations created new potential for highly active therapeutic interventions. After discovery of ALK rearrangements in NSCLC, it was recognized that these confer sensitivity to ALK inhibition. Areas covered: Crizotinib, the first-in-class ALK/ROS1/MET inhibitor, was initially approved as second-line treatment of ALK-positive advanced NSCLC but after this, i...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
More News: Addiction | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Lung Cancer | Neurology | Non-Small Cell Lung Cancer